Health Regeneron’s antibody drug cuts COVID-19 risk by nearly 82% for up to 8 months By - November 8, 2021 0 229 Facebook Twitter Pinterest WhatsApp Regeneron’s antibody therapy, REGEN-COV, is currently authorized in the U.S.